Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsResearch in context

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsResearch in context

Summary: Background: Neurofilament light chain (NfL), a neuronal cytoskeletal protein that is released upon neuroaxonal injury, is associated with multiple sclerosis (MS) relapsing activity and has demonstrated some prognostic ability for future relapse-related disease progression, yet its value in...

Full description

Bibliographic Details
Main Authors: Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, Corrado Bernasconi, Ulrike Bonati, Anne H. Cross, Saloumeh Fischer, Laura Gaetano, Stephen L. Hauser, Robert Hendricks, Ludwig Kappos, Jens Kuhle, David Leppert, Fabian Model, Annette Sauter, Harold Koendgen, Xiaoming Jia, Ann E. Herman
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:EBioMedicine
Subjects:
Multiple sclerosis
Ocrelizumab
NfL
Biomarker
Disease progression
Online Access:http://www.sciencedirect.com/science/article/pii/S235239642300227X

Internet

http://www.sciencedirect.com/science/article/pii/S235239642300227X

Similar Items